NVUS - Novus Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

Novus Therapeutics, Inc.

19900 MacArthur Boulevard
Suite 550
Irvine, CA 92612
United States

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Gregory J. FlesherCEO & DirectorN/AN/A1970
Dr. Catherine C. Turkel PharmD, MBA, Ph.D.PresN/AN/A1961
Mr. Jon Kuwahara CPASr. VP of Fin. & Admin.N/AN/A1965
Ms. Christine G. Ocampo CPAConsultantN/AN/A1972
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Novus Therapeutics, Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of ear, nose, and throat products. Its lead product is a nasally-administered combination drug product (OP-02) intended to address the underlying cause of otitis media and Eustachian tube dysfunction (OM/ETD) conditions. The company also has a foam-based drug delivery technology platform (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities. It is developing a foam-based combination drug-product to the external ear canal that is an improved treatment option for acute otitis externa. The company is headquartered in Irvine, California.

Corporate Governance

Novus Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.